Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004400 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
A Phase 2 study of HIV Infections and Cachexia, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT00004400 is a Phase 2 study of HIV Infections and Cachexia that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 56 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00004400, a Phase 2 study of HIV Infections and Cachexia, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women. II. Examine the mechanism of testosterone-induced increase in fat-free mass.
Conditions Studied
Interventions
- DRUG testosterone
Study Locations (3)
California
- Charles R. Drew University of Medicine and Science - Los Angeles
- Los Angeles County Harbor-UCLA Medical Center - Torrance
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 1997-04 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004400
The ClinicalTrials.gov registry entry for NCT00004400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which testosterone is the first listed.
NCT00004400 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Missouri.
Frequently Asked Questions
What is clinical trial NCT00004400 about?
NCT00004400 is a clinical study titled "Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women". OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women. II. Examine the mechanism of testosterone-induced increase in fat-free mass.
What is the current status of trial NCT00004400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 1997-04. Estimated completion is 2001-09.
What conditions does trial NCT00004400 study?
This clinical trial studies the following conditions: HIV Infections, Cachexia.
What interventions are being tested in trial NCT00004400?
The interventions under investigation include: testosterone (DRUG).
Who is sponsoring clinical trial NCT00004400?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004400 being conducted?
This trial has 3 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.